FDA Deputy Oncology Director Dan Suzman describes approaches to oncology trials, including approaches to control arms in phase 3 trials and how results from multiple trials are considered. He also highlights the different approaches between accelerated and traditional approval. Dr. Suzman is a medical oncologist, and serves as deputy director of the Divison of Oncology 1 at the FDA, which focuses on GU malignancies, breast cancer, and gynecological malignancies. ...
The Uromigos: Prostate Cancer
Hear Thomas Powles, MD, and Brian Rini, MD, FASCO, discuss research and news on prostate cancer.
Advertisement
Dr. Tanya Dorff discusses her work on a phase 1 study investigating acapatamab for advanced prostate cancer.
Michael Lattanzi, MD, joins the podcast to discuss treatment plans and research in the community oncology setting.
Vania Wisdom, Senior Executive Editor at The Lancet, discusses cancer treatment and research in developing countries.
Dr. Dana Rathkopf describes the phase 1 data for the androgen receptor ligand-directed degrader in prostate cancer.
Dr. Agarwal discusses the CONTACT-02 trial that analyzed the use of cabozantinib in combination with atezolizumab for mCRPC.
Dr. Kim Chi discusses the BRCAAway and CONTACT-02 trials presented at ASCO GU 2024.
Dr. Himisha Beltran, describes the activity of novel agent HPN328 in neuroendocrine prostate cancer.
Neeraj Agarwal describes the results of the phase III CONTACT-02 trial on cabozantinib plus atezolizumab in prostate cancer.
...
Karim Fizazi, MD, PhD, joins the show to discuss the phase III TALAPRO-2 trial published in Nature.
Thomas Zilli joins the podcast to talk about the controversies surrounding radiotherapy for prostate cancer.
Silke Gillessen and Betrand Tombal discuss the questions which will address this issue at APCCC 2024.
Silke Gillessen gives an overview of APCCC 2024 taking place in Lugano, Switzerland, in April.
The Uromigos close out the year with Tanya Dorff, MD, as she discusses her favorite prostate cancer studies of 2023.
Dr. Rahul Aggarwal discusses his recent paper on a phase 1/2 study on Lu-177 with pembrolizumab for mCRPC.
Dr. Kevin Kelly discusses the AMG509 phase 1 study of xaluritamig, a bispecific T cell engager, for prostate cancer.
Louise Emmett discusses the phase 2 ENZA-p trial presented at ESMO 2023 on enzalutamide and 177Lu-PSMA-617 for mCRPC.
Dr. Nick James discusses the optimal patients to undergo radiotherapy for localized prostate cancer.
Dr. Michalski discusses brachytherapy techniques in prostate cancer, plus his work on a recent JCO article on the topic.
Jim Catto, PhD, FRCS, joins The Uromigos to discuss the 17-year follow-up data from the PROTECT prostate cancer study.
Dr. Susan F. Slovin discusses her recent paper that examined abiraterone with and without cabazitaxel for mCRPC.
Chana Weinstock, MD joins the podcast to give career advice and answer our questions about the FDA.
We're joined by Walter M. Stadler, MD, to discuss how academic papers are accepted and the steps to take when submitting one.
Neeraj Agarwal, MD, joins us to discuss the TALAPRO-2 study and the relevance of homologous recombination repair biomarkers.
Karim Fizazi, MD, PhD, discusses the radiotherapy components of the PEACE-1 study on abiraterone and prednisone added to ADT.
Karim Fizazi joins us at ASCO 2023 to discuss results from the TALAPRO-2 study on talazoparib plus enzalutamide for mCRPC.
Professor Nick James discusses the success of the STAMPEDE trial on the use of abiraterone in patients with prostate cancer.
An ODAC meeting determined that olaparib plus abiraterone for mCRPC should be restricted to patients with BRCA mutations.
Amar Kishan, MD, discusses his recent meta-analysis on the effects of concurrent neoadjuvant versus adjuvant sequencing.
The latest topics in urologic oncology are discussed at the 14th International Uro-Oncology Conference in Brazil.
Ursula Vogl, MD, discusses her research and career progression in the prostate and renal cell cancer fields.
Karine Tawagi, MD, from the University of Illinois, discusses her work in immune-related toxicities.
The Uromigos review ASCO GU 2023 data, including triplet vs doublet therapy, the ARASENS trial, and the ZIRCON phase 3 trial.
Neeraj Agarwal, MD, FASCO, describes positive data from the TALAPRO-2 study on talazoparib and enzalutamide for mCRPC.
Michael Morris, MD discusses PARP inhibition for castration-resistant prostate cancer and the differing opinions on its use.
The Uromigos discuss the cost of quality adjusted life years with Daniel Goldstein, MD, from Davidoff Cancer Center.
A summary of the prostate and bladder cancer session of the Conversations & Trending Topics in GU Cancers conference.
Chris Sweeney, MBBS, joins The Uromigos to discuss 2022 research as well as further studies to be carried out in 2023.
Drs. Silke Gillessen and Dan George debate the use of olaparib and abiraterone in selected or unselected patients with mCRPC.
The Uromigos chat with Axel Merseburger about his paper on continuing enzalutamide with docetaxel for the treatment of CRPC.
Rob Jones discusses the current state of PARP inhibition in prostate cancer as well as differing opinions on the treatment.
Silke Gillessen and Nick James discuss a randomized trial on duration of adjuvant/salvage androgen ablation with XRT.
Alex Wyatt joins The Uromigos to answer questions about ctDNA in prostate cancer and discuss his latest paper on that topic.
Declan Murphy and Matt Cooperberg debate the use of interventions in active surveillance for patients with prostate cancer.
Dr. Oliver Sartor, medical director of Tulane Cancer Center, discusses his career development and work in prostate cancer.
Neal Shore describes his recent controversial paper and the over-treatment of patients with low-grade disease.
Phillip Kuo discusses phase 3 of the VISION trial that utilizes Lutetium-177 for the treatment of prostate cancer.
Drs. Rana McKay and Kim Chi question whether doublet or triplet therapy is appropriate in the first-line.
Martin Stockler describes the ENZAMET trial, which shows mixed effects of enza on QOL in prostate cancer.
Dr. Stefano Fanti focuses on PSMA therapy PET CT, particularly when to use this as a diagnostic.
Dr. Fred Saad describes the results of the PROpel Phase III trial.
Advertisement
